INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
ISSN: 2348-5213 (Print), ISSN: 2348-5221 (Online)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 13, Issue 8- 2026

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2026.13.08.001

Biotechnological Approaches in Natural Product-Based Drug Discovery and Industrial Biotechnology: Current Advances and Future Perspectives

Hussein Muhammed[1], Yunusa Lawal[1], Ibrahim Usman[2]
[1]Department of Biochemistry, Prince Abubakar Audu University, Anyigba, Kogi State, Nigeria.
[2]Department of Biotechnology, Modibbo Adamawa University, Yola, Adamawa State, Nigeria.
#Correspondence: husseinmuhammed94@gmail.com

Abstract

Background: Natural products have remained one of the most important sources of therapeutic agents for centuries, contributing significantly to the discovery of antibiotics, anticancer drugs, immunosuppressants, and several other clinically useful compounds. Recent advances in biotechnology have transformed the discovery, production, and optimization of natural products by integrating genomic, metabolomic, and synthetic biology approaches with traditional natural product research.

Objective: This review examines recent developments in biotechnology-driven natural product-based drug discovery and industrial biotechnology, with emphasis on emerging technologies, their applications, current challenges, and future research directions.

Methods: A comprehensive literature review was conducted using peer-reviewed publications published between 2020 and 2026. Electronic databases including PubMed, Scopus, Web of Science, Google Scholar, ScienceDirect, and SpringerLink were systematically searched using predefined keywords related to natural products, biotechnology, drug discovery, metabolic engineering, synthetic biology, industrial biotechnology, genome mining, metabolomics, and artificial intelligence. Eligible studies were critically evaluated and synthesized to identify recent advances, industrial applications, knowledge gaps, and future prospects.

Results: Recent developments in genome mining, metabolomics, transcriptomics, synthetic biology, CRISPR-based genome editing, metabolic engineering, artificial intelligence, and machine learning have substantially accelerated natural product discovery while improving production efficiency. These technologies have enhanced the identification of novel bioactive compounds, optimized microbial and plant production systems, and expanded industrial applications in pharmaceuticals, nutraceuticals, agriculture, cosmetics, and environmental biotechnology. Despite these advances, challenges remain regarding scalability, regulatory approval, sustainable sourcing, and the integration of multidisciplinary datasets.

Conclusion: Biotechnology has reshaped natural product research by providing powerful tools for identifying, producing, and optimizing biologically active compounds. Continued integration of emerging technologies is expected to improve drug discovery efficiency, support sustainable industrial production, and expand the contribution of natural products to global healthcare.

Keywords: Natural products; biotechnology; drug discovery; industrial biotechnology; synthetic biology; metabolomics; genome mining; metabolic engineering; CRISPR; artificial intelligence

Graphical abstract



1. Introduction

Natural products have played a central role in medicine since the earliest civilizations. Plants, microorganisms, fungi, and marine organisms continue to provide structurally diverse molecules that serve either as therapeutic agents or as templates for the development of modern pharmaceuticals. Many widely prescribed drugs, including antibiotics, anticancer agents, immunosuppressants, antimalarials, and cholesterol-lowering medications, originate directly or indirectly from natural sources [1,2]. Even with remarkable progress in synthetic chemistry, approximately half of all approved drugs retain a direct connection to naturally occurring compounds, highlighting their continued importance in pharmaceutical innovation [3].

The renewed interest in natural products is largely driven by the increasing prevalence of antimicrobial resistance, cancer, metabolic disorders, neurodegenerative diseases, and emerging infectious diseases. These global health challenges have intensified the search for structurally novel compounds capable of acting on previously unexplored molecular targets [4]. Natural products remain particularly attractive because evolution has produced an enormous diversity of specialized metabolites with remarkable biological activities and high target specificity. Unlike many synthetic compound libraries, natural products possess unique chemical scaffolds that are often difficult to reproduce through conventional chemical synthesis [5].

Despite their immense potential, traditional natural product drug discovery has historically faced several limitations. Conventional bioassay-guided isolation is often labor-intensive, time-consuming, and associated with high rediscovery rates of previously known compounds. Furthermore, many microorganisms remain unculturable under standard laboratory conditions, preventing access to numerous biosynthetic pathways responsible for valuable secondary metabolites [6]. Similar challenges occur in medicinal plants, where environmental conditions, seasonal variations, and geographical differences influence metabolite composition, thereby affecting reproducibility and commercial production [7].

Advances in biotechnology have fundamentally changed this landscape. Modern genomic sequencing technologies now allow researchers to identify biosynthetic gene clusters that were previously inaccessible through conventional cultivation techniques. Genome mining has emerged as a powerful strategy for predicting novel natural products by identifying cryptic biosynthetic pathways within microbial genomes [8]. Likewise, transcriptomics and proteomics provide detailed insights into gene expression patterns and protein interactions that regulate metabolite biosynthesis, enabling researchers to manipulate metabolic pathways more efficiently [9].

Metabolomics has become another indispensable tool in natural product research by facilitating comprehensive profiling of small molecules produced by biological systems. The integration of high-resolution mass spectrometry, nuclear magnetic resonance spectroscopy, and sophisticated bioinformatics platforms has significantly improved metabolite identification and dereplication, thereby reducing the rediscovery of known compounds [10]. These technologies enable researchers to prioritize genuinely novel metabolites for further biological evaluation and drug development.

Synthetic biology has further accelerated natural product discovery by allowing complete redesign of biosynthetic pathways. Instead of relying solely on native organisms, scientists can now transfer biosynthetic gene clusters into genetically engineered microbial hosts with superior productivity. This strategy not only improves metabolite yield but also enables the production of structurally modified analogues with enhanced pharmacological properties [11]. Advances in metabolic engineering have similarly contributed to improved production of commercially valuable natural products through rational optimization of cellular metabolism.

The emergence of CRISPR-based genome editing has provided unprecedented precision for manipulating biosynthetic pathways involved in natural product synthesis. CRISPR technologies facilitate targeted activation or suppression of specific genes, allowing researchers to enhance metabolite production while simultaneously eliminating competing metabolic pathways [12]. Such approaches have substantially improved the feasibility of industrial-scale biosynthesis of pharmaceuticals, enzymes, biofuels, and nutraceuticals.

Artificial intelligence (AI) and machine learning (ML) are increasingly becoming integral components of biotechnology-assisted drug discovery. AI algorithms can rapidly analyze

extensive genomic, metabolomic, and chemical datasets to predict bioactivity, toxicity, pharmacokinetic properties, and potential molecular targets before experimental validation [13]. Machine learning models also assist in identifying biosynthetic gene clusters, optimizing fermentation conditions, and predicting successful metabolic engineering strategies. These computational advances reduce development costs while shortening the overall timeline for drug discovery.

Industrial biotechnology has benefited considerably from these technological developments. Microbial fermentation systems, recombinant DNA technology, enzyme engineering, and bioprocess optimization have enabled sustainable large-scale production of numerous bioactive compounds. Industries involved in pharmaceuticals, agriculture, food technology, cosmetics, and environmental remediation increasingly rely on biotechnology to improve production efficiency while minimizing environmental impact [14]. The adoption of renewable biological resources also supports global efforts toward sustainable manufacturing and circular bioeconomy initiatives.

Another notable trend involves the integration of multi-omics technologies. Combining genomics, transcriptomics, proteomics, metabolomics, and bioinformatics provides a systems-level understanding of complex biosynthetic networks. This integrated approach facilitates identification of regulatory mechanisms governing secondary metabolite production while revealing opportunities for targeted pathway engineering [15]. Such multidisciplinary strategies are rapidly becoming the standard framework for modern natural product research.

Although biotechnology has transformed natural product-based drug discovery, several important challenges remain. Scaling laboratory discoveries to industrial production often requires significant optimization because engineered microorganisms may exhibit reduced stability or productivity under commercial fermentation conditions.

Regulatory requirements for genetically modified organisms, intellectual property issues, sustainable sourcing of biological materials, and ethical considerations also continue to influence industrial implementation [16]. Furthermore, integrating massive multi-omics datasets requires advanced computational infrastructure and highly skilled multidisciplinary research teams.

The convergence of biotechnology, computational biology, systems biology, and data science is expected to redefine the future of natural product research. Emerging technologies promise not only to accelerate the discovery of new therapeutic agents but also to improve production sustainability, reduce manufacturing costs, and expand the range of commercially valuable natural products available for healthcare and industrial applications. Continued collaboration among academic institutions, biotechnology companies, pharmaceutical industries, and regulatory agencies will therefore be essential to translate these scientific advances into clinically and economically valuable products [17].

2. Methodology

2.1 Review Design

This review was conducted using a structured narrative review approach guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) framework. Although quantitative meta-analysis was not appropriate because of the heterogeneity of the included studies, the review adopted a transparent and reproducible methodology for literature identification, screening, selection, and synthesis. The primary objective was to evaluate recent advances in biotechnology-driven natural product-based drug discovery and industrial biotechnology published between January 2020 and March 2026.

2.2 Literature Search Strategy

Electronic literature searches were independently conducted in PubMed/MEDLINE, Scopus, Web

of Science Core Collection, Google Scholar, ScienceDirect, SpringerLink, and Wiley Online Library. Searches were performed using combinations of Medical Subject Headings (MeSH) and free-text keywords connected with Boolean operators.

The principal search string included:

("natural products" OR phytochemicals OR secondary metabolites OR microbial metabolites) AND ("drug discovery" OR pharmaceuticals) AND ("biotechnology" OR synthetic biology OR metabolic engineering OR genome mining OR metabolomics OR transcriptomics OR proteomics OR CRISPR OR artificial intelligence OR industrial biotechnology).

Manual searches of reference lists from eligible articles were also undertaken to identify additional relevant publications.

2.3 Eligibility Criteria

Studies were included if they:

- were published between 2020 and 2026;
- were written in English;
- were peer-reviewed;
- focused on biotechnology applications in natural product research or industrial biotechnology;
- reported recent technological advances, industrial applications, or future perspectives.

The following were excluded:
- conference abstracts;
- editorials;
- opinion papers lacking scientific evidence;
- duplicate publications;
- studies published before 2020;
- articles without accessible full texts.

2.4 Study Selection

Titles and abstracts retrieved from all databases were screened independently for relevance. Full-text articles satisfying the inclusion criteria were subsequently evaluated. Studies meeting all eligibility requirements were included in the final qualitative synthesis. Disagreements during study selection were resolved through repeated evaluation of the original publications until consensus was achieved.

2.5 Data Extraction and Synthesis

Relevant information extracted from eligible studies included publication year, study design, biotechnology platform investigated, natural product source, principal findings, industrial applications, major limitations, and future recommendations. The extracted information was synthesized thematically under major biotechnology approaches including genomics, metabolomics, synthetic biology, metabolic engineering, genome mining, CRISPR technology, artificial intelligence, and industrial biotechnology applications. The evidence was critically compared to identify emerging research trends, existing knowledge gaps, and future opportunities.

3. Natural Products as Sources of Drug Leads

Natural products continue to occupy a unique position in pharmaceutical research because they provide structurally diverse molecules that have evolved over millions of years to perform specific biological functions. Unlike many synthetic compounds, natural metabolites possess complex stereochemistry, diverse functional groups, and remarkable molecular architectures that enable selective interactions with biological targets. These characteristics make natural products invaluable starting points for drug discovery and lead optimization [18].

The contribution of natural products to modern medicine remains substantial. Recent analyses indicate that a significant proportion of newly approved small-molecule drugs either originate directly from natural products or are synthetic derivatives inspired by naturally occurring compounds. This sustained contribution reflects the unmatched chemical diversity of natural metabolites and their ability to address therapeutic targets that remain difficult to modulate using

conventional synthetic libraries [3,18]. Consequently, pharmaceutical companies and academic institutions continue to invest heavily in natural product research despite advances in combinatorial chemistry and high-throughput synthesis.

The biological diversity of terrestrial and marine ecosystems represents an enormous reservoir of bioactive compounds. Medicinal plants produce secondary metabolites such as alkaloids, flavonoids, terpenoids, phenolic acids, glycosides, saponins, tannins, lignans, and coumarins, many of which exhibit antimicrobial, anti-inflammatory, antioxidant, anticancer, antidiabetic, antiviral, and neuroprotective activities [19]. Likewise, microorganisms including bacteria, fungi, cyanobacteria, and actinomycetes synthesize numerous specialized metabolites that serve ecological functions while providing valuable pharmaceutical leads. Marine organisms such as sponges, algae, tunicates, mollusks, and marine microorganisms have also emerged as prolific sources of structurally unique metabolites with potent biological activities [20].

Microbial natural products remain particularly important because microorganisms possess remarkable biosynthetic capabilities. Species belonging to the genera Streptomyces, Bacillus, Pseudomonas, Penicillium, and Aspergillus continue to yield antibiotics, immunosuppressants, enzyme inhibitors, and anticancer compounds with significant therapeutic value [21]. Whole-genome sequencing has further demonstrated that many microorganisms harbor numerous cryptic biosynthetic gene clusters that remain silent under conventional laboratory conditions. These hidden pathways represent an enormous untapped resource for discovering novel natural products through genome-guided approaches [22].

Plant-derived metabolites continue to attract considerable attention because of their structural diversity and pharmacological versatility. Polyphenols, flavonoids, terpenes, alkaloids, and other phytochemicals have demonstrated broad biological activities in preclinical and clinical investigations. Beyond their direct therapeutic effects, many phytochemicals also serve as molecular scaffolds for designing safer and more potent synthetic analogues [23]. Modern phytochemical investigations increasingly combine traditional ethnopharmacological knowledge with advanced analytical techniques to improve the efficiency of lead identification and validation.

Marine natural products have experienced rapid growth as a research field during the past decade. The extreme environmental conditions found in marine ecosystems promote the evolution of chemically distinctive metabolites that are rarely encountered in terrestrial organisms. Several marine-derived compounds have progressed into clinical development for cancer, infectious diseases, and neurological disorders, illustrating the growing pharmaceutical importance of marine biodiversity [24]. Improved cultivation methods and metagenomic technologies have further expanded access to marine microbial metabolites that were previously inaccessible.

Despite this enormous chemical diversity, natural product drug discovery has traditionally encountered several obstacles. One of the most persistent challenges involves the repeated isolation of already known compounds, commonly referred to as rediscovery. This problem consumes considerable financial and scientific resources while reducing overall discovery efficiency [10]. Advances in metabolomics, molecular networking, and computational dereplication have significantly reduced this challenge by enabling rapid identification of previously characterized metabolites before extensive purification efforts are undertaken.

Another important limitation is the low natural abundance of many biologically active metabolites. Numerous promising compounds occur only in trace amounts within their native organisms, making commercial production difficult and environmentally unsustainable. Excessive harvesting of medicinal plants or marine organisms may also threaten biodiversity

and ecosystem stability [25]. Biotechnology has addressed many of these concerns by enabling heterologous expression, metabolic engineering, and microbial fermentation systems capable of producing target metabolites under controlled conditions.

Variability in metabolite composition represents another challenge in natural product research. Environmental conditions, geographical location, climate, soil composition, developmental stage, seasonal variation, and biotic stress all influence secondary metabolite production in medicinal plants [7]. Such variability complicates quality control and limits reproducibility during pharmaceutical development. Modern analytical technologies, including metabolomic fingerprinting and standardized cultivation systems, now provide more reliable approaches for ensuring product consistency.

The increasing burden of antimicrobial resistance has renewed global interest in natural products as sources of novel antibiotics. Conventional antimicrobial pipelines have slowed considerably over recent decades, whereas resistant pathogens continue to emerge worldwide. Natural products offer structurally novel molecules capable of acting through previously unexplored mechanisms, making them particularly valuable for combating multidrug-resistant microorganisms [26]. Similar opportunities exist in oncology, where natural products continue to inspire innovative anticancer therapies targeting complex cellular pathways.Beyond pharmaceutical applications, natural products contribute significantly to industrial biotechnology. Bioactive metabolites are increasingly incorporated into nutraceuticals, functional foods, cosmetics, agricultural biopesticides, animal feed additives, and environmentally friendly industrial products [27]. Consumer demand for naturally derived products has stimulated further investment in sustainable production technologies capable of meeting commercial requirements without compromising biodiversity conservation.

Recent advances in biotechnology have fundamentally altered how natural products are discovered and developed. Instead of relying exclusively on conventional extraction and bioassay-guided fractionation, researchers now integrate genomic sequencing, metabolomics, transcriptomics, synthetic biology, artificial intelligence, and systems biology into comprehensive discovery platforms. These multidisciplinary approaches have accelerated lead identification while substantially improving production efficiency and reducing development costs [28]. As these technologies continue to mature, natural products are expected to remain one of the most productive sources of future therapeutic agents.

4. Biotechnological Platforms Driving Natural Product-Based Drug Discovery

The rapid advancement of biotechnology has transformed natural product research from a largely empirical discipline into a data-driven and highly integrated scientific field. Conventional bioassay-guided isolation, although responsible for numerous landmark discoveries, is often constrained by low throughput, repeated isolation of known compounds, and the inability to exploit the vast biosynthetic potential of uncultivable organisms. Modern biotechnological platforms now integrate genomics, transcriptomics, proteomics, metabolomics, bioinformatics, and systems biology to accelerate the discovery of novel bioactive molecules while improving production efficiency and reducing development time [29]. These complementary technologies have substantially increased the probability of identifying previously unknown natural products and have expanded opportunities for industrial biotechnology.

4.1 Genomics in Natural Product Discovery

The widespread adoption of next-generation sequencing has revolutionized natural product research by providing complete genome sequences for thousands of microorganisms, medicinal plants, and marine organisms. Genome sequencing enables researchers to identify genes

involved in secondary metabolite biosynthesis, predict metabolic capabilities, and investigate evolutionary relationships among biosynthetic pathways [30]. Unlike traditional approaches that depend on metabolite isolation, genomics provides a predictive framework that identifies promising biosynthetic pathways before laboratory experimentation.

One of the greatest contributions of genomics has been the discovery that many microorganisms possess significantly more biosynthetic gene clusters than previously recognized. Genome analyses of Streptomyces, Bacillus, Aspergillus, and other prolific producers have revealed numerous cryptic biosynthetic pathways that remain transcriptionally silent under routine laboratory conditions [31]. These findings suggest that only a small proportion of microbial chemical diversity has been experimentally explored.Comparative genomics has further enhanced natural product discovery by identifying conserved biosynthetic genes across related species while simultaneously revealing unique gene clusters associated with novel metabolites. Comparative analyses also facilitate the identification of evolutionary events such as gene duplication, horizontal gene transfer, and pathway diversification that contribute to chemical diversity [32]. Such information assists researchers in prioritizing organisms with the greatest potential for producing structurally novel compounds.

Plant genomics has experienced remarkable progress during the past decade. High-quality chromosome-level genome assemblies are now available for numerous medicinal plants, allowing detailed investigation of genes responsible for alkaloid, flavonoid, terpenoid, and phenolic biosynthesis [33]. These genomic resources provide valuable information for molecular breeding, metabolic engineering, and conservation of medicinal plant biodiversity.

4.2 Genome Mining

Genome mining represents one of the most influential biotechnology tools currently available for natural product discovery. This strategy combines computational biology with genome sequence analysis to identify biosynthetic gene clusters encoding potentially valuable secondary metabolites. Instead of relying on random screening, genome mining directs attention toward organisms possessing genetically encoded biosynthetic potential [34].

Several computational platforms, including antiSMASH, PRISM, DeepBGC, and related bioinformatic pipelines, have become indispensable for predicting biosynthetic pathways from genomic data [35]. These programs identify characteristic biosynthetic enzymes such as polyketide synthases, non-ribosomal peptide synthetases, terpene cyclases, and ribosomally synthesized and post-translationally modified peptide pathways. Computational predictions subsequently guide experimental validation through genetic manipulation, metabolomics, or heterologous expression.

Genome mining has proven particularly valuable for discovering cryptic metabolites from microorganisms that cannot be readily cultured under conventional laboratory conditions. Metagenomic sequencing now permits direct analysis of environmental DNA obtained from soil, marine sediments, plant-associated microbiomes, and extreme environments without prior microbial isolation [36]. These uncultured microbial communities contain enormous biosynthetic diversity that was previously inaccessible using traditional microbiological techniques.

Recent advances in long-read sequencing technologies have further improved genome mining by generating highly contiguous genome assemblies that facilitate accurate identification of complete biosynthetic gene clusters. Combined with improved annotation algorithms, these technologies continue to expand the catalogue of candidate pathways available for pharmaceutical development [37].

4.3 Transcriptomics

While genomics identifies the genetic potential of an organism, transcriptomics determines which genes are actively expressed under specific physiological or environmental conditions. Transcriptomic analysis therefore provides dynamic information regarding regulation of biosynthetic pathways responsible for natural product formation [38].

RNA sequencing has become the principal technology for transcriptomic investigations because it offers high sensitivity, broad dynamic range, and accurate quantification of gene expression. Comparative transcriptomic analyses performed under different environmental conditions enable identification of regulatory genes controlling secondary metabolite biosynthesis [39]. This information allows researchers to manipulate culture conditions or genetic regulators to increase production of valuable metabolites.

In medicinal plants, transcriptomics has facilitated the identification of enzymes responsible for biosynthesis of numerous pharmacologically important compounds, including flavonoids, alkaloids, terpenoids, and phenolic acids. Integration of transcriptomic data with metabolite profiling has clarified several previously unknown biosynthetic pathways and has accelerated functional characterization of candidate genes [40].

Transcriptomic investigations also support metabolic engineering by identifying rate-limiting enzymatic steps and regulatory bottlenecks that restrict metabolite production. Manipulating these key regulatory genes frequently results in significant increases in biosynthetic efficiency and product yield [41].

4.4 Proteomics

Proteomics complements genomic and transcriptomic analyses by directly characterizing proteins responsible for cellular metabolism. Since proteins constitute the functional products of gene expression, proteomic investigations provide important insights into enzyme abundance, post-translational modifications, protein-protein interactions, and metabolic regulation [42].

Advances in liquid chromatography coupled with tandem mass spectrometry have greatly improved proteome coverage and quantitative protein analysis. Modern proteomic workflows can identify thousands of proteins simultaneously, allowing comprehensive evaluation of metabolic pathways associated with secondary metabolite biosynthesis [43].Proteomic investigations frequently reveal discrepancies between gene expression and protein abundance, emphasizing the importance of examining multiple biological layers rather than relying solely on transcriptomic information. Such integrated analyses provide a more complete understanding of the molecular mechanisms controlling natural product production [44].

Proteomics has also contributed to industrial biotechnology by identifying enzymes with desirable catalytic properties for pharmaceutical manufacturing, food biotechnology, environmental remediation, and green chemistry. Protein engineering strategies derived from proteomic studies continue to improve enzyme stability, substrate specificity, and catalytic efficiency under industrial conditions [45].

4.5 Metabolomics

Among all omics technologies, metabolomics provides the closest representation of the biochemical phenotype because it directly measures small molecules synthesized by living organisms. Metabolomic profiling has therefore become one of the most powerful tools for natural product discovery, quality control, and dereplication [46].

Modern metabolomic investigations rely primarily on ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry, gas chromatography-mass spectrometry, and nuclear magnetic resonance

spectroscopy. These analytical platforms provide comprehensive chemical fingerprints capable of identifying thousands of metabolites within highly complex biological extracts [47].One of the major contributions of metabolomics is rapid dereplication. By comparing spectral information against publicly available databases and molecular networking platforms, researchers can rapidly distinguish previously characterized compounds from genuinely novel metabolites, thereby reducing unnecessary purification efforts and accelerating discovery [48].

Molecular networking has become an especially valuable computational approach for organizing tandem mass spectrometry datasets according to structural similarity. Closely related metabolites cluster together, enabling researchers to identify unknown analogues belonging to established natural product families and prioritize promising extracts for isolation [49].

Integration of metabolomics with genomics has emerged as a particularly powerful strategy. Genome mining predicts biosynthetic capability, whereas metabolomics confirms actual metabolite production. Combining these complementary datasets substantially increases confidence during natural product identification and facilitates assignment of biosynthetic gene clusters to their corresponding metabolites [50]. Such multi-omics integration is rapidly becoming the standard workflow for contemporary natural product research.

4.6 Synthetic Biology in Natural Product Drug Discovery

Synthetic biology has emerged as one of the most transformative biotechnological approaches for natural product research by combining molecular biology, genetic engineering, systems biology, computational biology, and engineering principles to redesign biological systems for the efficient production of valuable metabolites [51]. Unlike conventional strain improvement techniques that rely on random mutagenesis or optimization of fermentation conditions, synthetic biology enables the rational construction and manipulation of entire biosynthetic pathways. This approach has significantly expanded the range of natural products that can be produced at laboratory and industrial scales while reducing dependence on scarce biological resources.

A major advantage of synthetic biology lies in its ability to reconstruct complete biosynthetic pathways in heterologous hosts. Many medicinal plants and marine organisms produce bioactive compounds in extremely low concentrations, making commercial extraction economically impractical and environmentally unsustainable [52]. By transferring biosynthetic gene clusters into genetically tractable microorganisms such as Escherichia coli, Saccharomyces cerevisiae, or Streptomyces species, researchers can achieve stable and scalable production of valuable metabolites under controlled fermentation conditions [53].

Synthetic biology also facilitates pathway refactoring, whereby biosynthetic genes are reorganized, redesigned, and regulated to maximize metabolite production. Native regulatory mechanisms often limit biosynthetic efficiency because secondary metabolites are produced only under specific environmental conditions or developmental stages. Through promoter engineering, codon optimization, ribosome binding site modification, and synthetic regulatory circuits, these constraints can be overcome to substantially increase metabolite yields [54].

An equally important application involves the generation of novel natural product analogues. Biosynthetic enzymes frequently exhibit substrate flexibility, allowing researchers to introduce alternative precursor molecules into engineered pathways. This strategy produces structural analogues that may exhibit improved pharmacological activity, enhanced stability, reduced toxicity, or superior pharmacokinetic properties compared with their naturally occurring counterparts [55]. Such biosynthetic diversification considerably expands chemical space beyond what is available in nature.

Cell-free synthetic biology has also attracted increasing attention as an alternative production platform. Instead of relying on living cells, cell-free systems employ purified enzymes or cellular extracts to synthesize target metabolites in vitro. These systems eliminate several physiological constraints associated with microbial growth while providing greater experimental control over metabolic reactions [56]. Cell-free biosynthesis has demonstrated considerable promise for rapid pathway prototyping and production of compounds that are toxic to living cells.

Computational modelling has become an indispensable component of synthetic biology. Genome-scale metabolic models, flux balance analysis, and machine learning algorithms enable prediction of metabolic bottlenecks before experimental implementation [57]. These computational approaches reduce development time while improving the efficiency of pathway engineering and strain optimization.Despite remarkable progress, several challenges continue to limit broader industrial application of synthetic biology. Engineered pathways often impose substantial metabolic burdens on host organisms, reducing growth rates and long-term genetic stability. In addition, balancing precursor availability, cofactor regeneration, and energy metabolism remains a major challenge during large-scale production [58]. Future developments in systems biology, automated design platforms, and adaptive laboratory evolution are expected to address many of these limitations.

4.7 Metabolic Engineering

Metabolic engineering represents another cornerstone of biotechnology-driven natural product discovery and industrial biotechnology. It involves the deliberate modification of cellular metabolic networks to improve production of target metabolites through genetic manipulation of biosynthetic enzymes, transport systems, regulatory proteins, and competing metabolic pathways [59].

Recent advances in metabolic engineering have significantly improved the commercial production of antibiotics, anticancer compounds, pigments, vitamins, enzymes, amino acids, organic acids, and numerous plant secondary metabolites. Rather than relying solely on naturally occurring biosynthetic capacities, researchers can now redirect carbon flux toward desired products through rational manipulation of metabolic pathways [60].

One common strategy involves overexpression of rate-limiting enzymes responsible for metabolite biosynthesis. Increasing expression of these enzymes frequently enhances metabolic flux toward target compounds, resulting in substantially improved product yields [61]. Conversely, deletion or suppression of competing metabolic pathways conserves precursor molecules that would otherwise be diverted away from the desired biosynthetic route.

Dynamic metabolic regulation has become increasingly important in modern metabolic engineering. Instead of constitutively expressing all biosynthetic genes, synthetic regulatory systems adjust enzyme expression according to cellular metabolic status. Such dynamic control minimizes metabolic burden while maintaining high productivity throughout the fermentation process [62].

Advances in systems metabolic engineering now integrate genomics, transcriptomics, proteomics, metabolomics, and computational biology to provide comprehensive understanding of cellular physiology. This holistic approach facilitates identification of regulatory bottlenecks that cannot be detected through conventional metabolic engineering strategies alone [63]. Multi-omics integration therefore represents a major step toward the development of highly efficient microbial cell factories.Several industrial success stories illustrate the impact of metabolic engineering. Engineered microorganisms have been successfully developed for commercial biosynthesis of artemisinin precursors, carotenoids, flavonoids, taxol intermediates, resveratrol, vanillin, and numerous pharmaceutical ingredients [64]. These achievements have reduced production costs

while decreasing dependence on seasonal plant harvesting.

Metabolic engineering also contributes significantly to environmental sustainability. Biological production systems generally require lower energy input than conventional chemical synthesis and frequently utilize renewable feedstocks such as glucose, agricultural residues, or industrial waste streams [65]. Consequently, engineered microbial fermentation supports the transition toward a circular bioeconomy characterized by reduced greenhouse gas emissions and improved resource utilization.The future of metabolic engineering is expected to benefit from continued integration with artificial intelligence, robotic automation, digital bioprocess monitoring, and high-throughput genome editing. These technologies will enable rapid optimization of thousands of genetic designs simultaneously, thereby accelerating strain development for pharmaceutical and industrial biotechnology applications [66].

4.8 CRISPR Technology in Natural Product Research

The discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated proteins has revolutionized genome engineering by providing an accurate, versatile, and relatively simple method for targeted genetic modification [67]. Since its introduction into biotechnology, CRISPR has become one of the most influential tools for improving natural product discovery and production.

CRISPR technology enables precise deletion, insertion, activation, or repression of genes involved in secondary metabolite biosynthesis. Unlike conventional genetic engineering methods that often require multiple rounds of mutation and selection, CRISPR allows rapid modification of biosynthetic pathways with high specificity [68]. This precision has accelerated functional characterization of biosynthetic genes in microorganisms, medicinal plants, and filamentous fungi.One of the most valuable applications of CRISPR involves activation of silent biosynthetic gene clusters. Numerous microorganisms possess cryptic pathways that remain transcriptionally inactive under laboratory conditions. CRISPR activation systems can selectively stimulate expression of these dormant clusters, leading to production of previously unknown natural products [69]. This strategy has dramatically expanded the chemical diversity available for pharmaceutical screening.

CRISPR interference has likewise become an effective approach for redirecting metabolic flux toward desired products. Selective repression of competing pathways increases precursor availability for target metabolite biosynthesis, thereby improving production efficiency without permanently altering genome integrity [70].

Multiplex genome editing further enhances CRISPR applications by allowing simultaneous modification of several genes within a single experiment. This capability is particularly valuable for complex biosynthetic pathways involving numerous enzymes and regulatory proteins [71]. Multiplex editing substantially reduces experimental time while enabling comprehensive pathway optimization.In industrial biotechnology, CRISPR has improved microbial production strains by enhancing stress tolerance, substrate utilization, fermentation efficiency, and product yield [72]. Similar advances have been reported in medicinal plants, where genome editing contributes to improved phytochemical production, disease resistance, and crop productivity.

Despite its remarkable versatility, CRISPR technology still faces important challenges. Off-target mutations, delivery efficiency, regulatory concerns, and public acceptance remain important considerations for commercial implementation [73]. Continued refinement of genome-editing technologies is expected to improve editing precision while facilitating wider industrial adoption.

The integration of CRISPR with synthetic biology, metabolic engineering, and artificial

intelligence is likely to define the next generation of biotechnology-assisted natural product research. Together, these complementary technologies provide unprecedented opportunities to accelerate drug discovery while promoting sustainable industrial production of valuable natural products [74].

4.9 Artificial Intelligence and Machine Learning in Natural Product Drug Discovery

Artificial intelligence (AI) and machine learning (ML) have become indispensable components of modern drug discovery by enabling rapid analysis of complex biological and chemical datasets that would otherwise require extensive experimental investigation [75]. The integration of AI into natural product research has transformed virtually every stage of the discovery pipeline, including target identification, compound prioritization, structural elucidation, biological activity prediction, toxicity assessment, pharmacokinetic evaluation, and lead optimization. As the volume of genomic, metabolomic, and chemical information continues to increase, AI has emerged as a powerful tool for extracting biologically meaningful patterns from multidimensional datasets.

One of the most significant contributions of AI is the prediction of biological activity based on chemical structure. Traditional screening approaches require thousands of compounds to be experimentally tested before identifying a few promising candidates. Machine learning algorithms trained on large chemical databases can predict the probability that newly identified natural products will exhibit antimicrobial, anticancer, antiviral, anti-inflammatory, or antidiabetic activities before laboratory validation [76]. Such predictive models substantially reduce the cost and time associated with early-stage drug discovery.

Deep learning has further improved virtual screening by identifying subtle structural features that influence biological activity. Unlike conventional quantitative structure-activity relationship (QSAR) models, deep neural networks can analyse highly complex molecular representations without requiring manual feature selection [77]. These models have demonstrated remarkable accuracy in predicting ligand-receptor interactions, enzyme inhibition, and molecular binding affinity, thereby improving the efficiency of lead identification.

Artificial intelligence also plays an important role in natural product dereplication. High-resolution mass spectrometry generates enormous datasets that are often difficult to interpret manually. AI-assisted spectral analysis enables rapid comparison of experimental spectra with existing metabolite databases, allowing researchers to distinguish known compounds from potentially novel metabolites [78]. This capability minimizes unnecessary purification of previously reported compounds and allows greater emphasis on genuinely new chemical entities.

Natural language processing has become another valuable application of AI in pharmaceutical research. Millions of scientific publications contain important information regarding medicinal plants, microbial metabolites, pharmacological activities, biosynthetic pathways, and clinical investigations. AI-driven text mining systems can rapidly extract relevant information from this literature, identify previously overlooked relationships, and generate new research hypotheses that would be difficult to recognize through manual review [79].

Machine learning has similarly improved genome mining by predicting biosynthetic gene clusters with greater accuracy than traditional bioinformatic algorithms. Advanced learning models recognise conserved sequence patterns, enzyme architectures, and regulatory signatures associated with secondary metabolite biosynthesis, thereby increasing the likelihood of discovering novel natural products from newly sequenced genomes [80].

Another rapidly developing application involves prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Drug candidates frequently fail during clinical

development because of poor pharmacokinetic behaviour or unacceptable toxicity. AI models can estimate these properties during the earliest stages of discovery, allowing unsuitable compounds to be eliminated before expensive laboratory and clinical investigations are undertaken [81].

Artificial intelligence is increasingly integrated with robotic automation and high-throughput experimentation. Automated laboratories equipped with robotic systems can perform thousands of biological assays under AI-guided experimental designs, continuously updating predictive models as new experimental data become available [82]. This closed-loop approach significantly accelerates optimization of natural product-derived drug candidates while reducing human error.

Despite these remarkable achievements, AI remains dependent on the quality of available data. Incomplete databases, inconsistent experimental methodologies, limited chemical diversity, and biased training datasets may reduce predictive performance and limit model generalizability [83]. Furthermore, many sophisticated AI algorithms operate as "black-box" models whose predictions are difficult to interpret biologically, creating challenges for regulatory acceptance and scientific validation.

Future developments are expected to focus on explainable artificial intelligence, federated learning, digital twins, and multimodal machine learning capable of integrating genomic, transcriptomic, proteomic, metabolomic, structural, and clinical datasets simultaneously [84]. Such advances are likely to further accelerate natural product drug discovery while improving confidence in computational predictions.

5. Industrial Biotechnology Applications of Natural Products

Industrial biotechnology has evolved into one of the most dynamic sectors of the global bioeconomy by applying biological systems to the sustainable production of pharmaceuticals, chemicals, food ingredients, biofuels, agricultural products, cosmetics, and environmental remediation technologies [85]. The integration of biotechnology with natural product research has expanded the commercial utilization of bioactive compounds while promoting environmentally responsible manufacturing practices.

5.1 Pharmaceutical Biotechnology

The pharmaceutical industry remains the largest consumer of natural product-derived compounds. Numerous antibiotics, anticancer agents, immunosuppressants, antifungal drugs, antiparasitic agents, and cardiovascular medications continue to originate from microorganisms and medicinal plants [86]. Biotechnology has substantially improved the production of these compounds through recombinant DNA technology, metabolic engineering, synthetic biology, and optimized fermentation processes.

Microbial fermentation has become the preferred manufacturing platform for many pharmaceutical products because it offers consistent product quality, scalability, and reduced dependence on seasonal biological resources [87]. Advances in bioprocess engineering have increased production yields while minimizing manufacturing costs and environmental impact.

Recombinant microorganisms are now widely employed to produce therapeutic proteins, peptide antibiotics, vaccine components, and biologically active metabolites. Continuous improvements in strain engineering and fermentation optimization have expanded the commercial feasibility of numerous natural product-derived pharmaceuticals [88].

5.2 Nutraceuticals and Functional Foods

Growing consumer interest in preventive healthcare has stimulated rapid expansion of the nutraceutical and functional food industries. Bioactive compounds including flavonoids, carotenoids, polyphenols, omega-3 fatty acids,

dietary fibres, probiotics, prebiotics, and plant-derived antioxidants are increasingly incorporated into food products intended to promote health beyond basic nutrition [89].

Industrial biotechnology supports this sector by improving cultivation systems, optimizing extraction technologies, enhancing metabolite stability, and developing sustainable microbial production platforms [90]. Encapsulation technologies, nanoformulations, and controlled-release systems further improve bioavailability and shelf life of nutraceutical ingredients.

The application of precision fermentation has also enabled commercial production of high-value food ingredients that were previously obtainable only through extensive plant extraction or animal sources. Such innovations contribute to sustainable food production while meeting increasing global demand for functional foods [91].

5.3 Agricultural Biotechnology

Agriculture represents another major beneficiary of natural product biotechnology. Plant-derived pesticides, microbial biofertilizers, biostimulants, and biological control agents provide environmentally friendly alternatives to synthetic agrochemicals [92]. These biological products reduce environmental pollution, improve soil health, and contribute to sustainable crop production.

Natural products such as microbial lipopeptides, essential oils, botanical extracts, and secondary metabolites exhibit insecticidal, fungicidal, herbicidal, and nematicidal activities that support integrated pest management programmes [93]. Biotechnology has improved commercial production of these compounds through microbial fermentation, metabolic engineering, and formulation science.

Advances in plant biotechnology have also enabled development of crop varieties with improved resistance to pests, diseases, drought, and salinity while simultaneously enhancing production of nutritionally valuable phytochemicals [94].

5.4 Cosmetic Biotechnology

The cosmetic industry increasingly utilizes natural products because consumers generally perceive plant-derived and microbial ingredients as safer and more environmentally sustainable than synthetic alternatives [95]. Biotechnology has expanded access to natural pigments, antioxidants, moisturizing agents, antimicrobial compounds, collagen stimulators, and anti-ageing ingredients through sustainable production systems.

Microbial fermentation now supplies numerous cosmetic ingredients including hyaluronic acid, ceramides, biosurfactants, enzymes, vitamins, and natural fragrances [96]. Advances in synthetic biology continue to diversify the range of commercially available cosmetic bioactives while improving production efficiency and quality consistency.

5.5 Environmental Biotechnology

Environmental biotechnology applies natural products and biological systems to pollution control, waste management, renewable energy production, and ecosystem restoration [97]. Microorganisms capable of degrading petroleum hydrocarbons, pesticides, plastics, dyes, and heavy metals have become increasingly important in environmental remediation programmes.

Bioremediation utilizes naturally occurring or engineered microorganisms to detoxify contaminated environments through enzymatic degradation or transformation of hazardous pollutants. Compared with conventional physicochemical treatment methods, biological remediation is generally less expensive, more sustainable, and environmentally compatible [98]. Natural enzymes have also found widespread industrial application in wastewater treatment, textile processing, food manufacturing, paper production, and biofuel generation because they function under relatively mild conditions while

reducing chemical consumption and energy requirements [99].

The convergence of biotechnology, systems biology, artificial intelligence, and green chemistry is expected to further strengthen the contribution of natural products to sustainable industrial development. Future industries will increasingly depend on renewable biological resources and precision biomanufacturing to meet growing global demand while minimizing environmental impact [100].

6. Current Challenges and Limitations

Despite the remarkable progress achieved through biotechnology, several scientific, technical, economic, and regulatory challenges continue to limit the full exploitation of natural products in drug discovery and industrial biotechnology. Addressing these limitations will be essential to translating laboratory discoveries into commercially viable pharmaceutical products and sustainable industrial applications [101].

6.1 Complexity of Natural Product Chemistry

Natural products possess exceptional structural diversity, which contributes significantly to their pharmacological potential. However, this structural complexity also presents considerable analytical challenges. Many bioactive metabolites occur as complex mixtures containing numerous structurally related analogues, stereoisomers, and metabolites with very similar physicochemical properties [102]. The isolation, purification, and structural elucidation of these compounds often require sophisticated analytical techniques, including high-resolution mass spectrometry, multidimensional nuclear magnetic resonance spectroscopy, and X-ray crystallography. These technologies are expensive, technically demanding, and not readily available in many research institutions.

Another challenge involves the extremely low abundance of numerous pharmacologically important metabolites. Valuable compounds may be present only in trace concentrations, requiring the processing of large quantities of biological material before sufficient amounts can be obtained for biological evaluation and clinical development [103]. Such limitations increase production costs and may threaten biodiversity when medicinal plants or marine organisms are harvested unsustainably.

6.2 Difficulties in Culturing Natural Product-Producing Organisms

Microorganisms remain one of the richest sources of bioactive secondary metabolites. However, it is estimated that the vast majority of environmental microorganisms cannot be cultivated using conventional laboratory techniques [104]. Consequently, a substantial proportion of microbial biosynthetic diversity remains inaccessible through traditional fermentation-based discovery programmes.

Although metagenomics and genome mining have expanded access to uncultured microorganisms, functional expression of their biosynthetic pathways remains technically challenging. Many biosynthetic gene clusters require complex regulatory networks, specialized precursor molecules, or environmental signals that are absent in heterologous host organisms [105]. Improving cultivation methods and developing more versatile expression platforms therefore remain important priorities.

6.3 Bottlenecks in Metabolic Engineering

Metabolic engineering has substantially improved production of numerous natural products, yet several biological constraints continue to limit industrial implementation. Introduction of complex biosynthetic pathways frequently imposes metabolic stress on engineered microorganisms, reducing growth rates, genetic stability, and overall productivity [106].

Competition between endogenous metabolic pathways and engineered biosynthetic routes often limits precursor availability for target

metabolite production. Furthermore, accumulation of intermediate compounds may produce cellular toxicity that reduces fermentation efficiency [107]. Continued advances in systems biology, dynamic pathway regulation, and computational metabolic modelling are expected to alleviate many of these bottlenecks.

6.4 Data Integration and Bioinformatics Challenges

The rapid expansion of omics technologies has generated unprecedented volumes of biological data. Genomics, transcriptomics, proteomics, metabolomics, and phenomics collectively produce complex datasets that require advanced computational analysis and interpretation [108]. Integrating these diverse datasets into coherent biological models remains one of the greatest challenges facing modern biotechnology.

Differences in experimental design, analytical platforms, data formats, and statistical methodologies frequently complicate cross-study comparisons. In addition, incomplete metabolite databases and inconsistent compound annotation reduce the accuracy of computational predictions [109]. Continued development of standardized analytical pipelines and interoperable databases will be essential for maximizing the value of multi-omics research.

6.5 Regulatory and Ethical Considerations

The commercialization of biotechnology-derived products is governed by rigorous regulatory frameworks intended to ensure product safety, efficacy, and environmental protection. Genetically engineered microorganisms, genome-edited organisms, recombinant pharmaceuticals, and synthetic biology products must undergo comprehensive safety assessments before receiving regulatory approval [110].

Regulatory requirements often differ considerably among countries, creating challenges for international commercialization and technology transfer. Intellectual property protection, benefit sharing, access to genetic resources, and compliance with international agreements such as the Nagoya Protocol also influence natural product research and commercialization [111].Ethical concerns surrounding genetic modification, synthetic biology, and artificial intelligence further emphasize the importance of transparent governance, responsible innovation, and public engagement throughout the development process.

6.6 Economic Constraints

Drug discovery remains an expensive and time-consuming process. Although biotechnology has accelerated many aspects of natural product research, the overall cost of pharmaceutical development remains substantial. High-throughput analytical instrumentation, genome sequencing, computational infrastructure, bioprocess optimization, and clinical trials require significant financial investment [112].

Many promising discoveries originating from academic laboratories fail to progress toward commercialization because of limited funding, inadequate industrial partnerships, or insufficient technology transfer mechanisms. Strengthening collaborations among universities, research institutes, biotechnology companies, pharmaceutical industries, and government agencies will therefore be essential for translating scientific discoveries into marketable products [113].

6.7 Sustainability and Biodiversity Conservation

Natural product research depends heavily on biological diversity. Unsustainable harvesting of medicinal plants, marine organisms, and microorganisms may threaten fragile ecosystems while reducing future opportunities for drug discovery [114]. Climate change, habitat destruction, pollution, invasive species, and overexploitation further accelerate biodiversity loss worldwide.

Biotechnology provides several sustainable alternatives, including plant tissue culture,

microbial fermentation, synthetic biology, metabolic engineering, and heterologous expression systems. Nevertheless, long-term conservation of biological resources remains fundamental to ensuring continued access to novel bioactive compounds [115].

7. Future Perspectives

The future of natural product-based drug discovery will depend increasingly on multidisciplinary integration rather than isolated technological advances. The convergence of biotechnology, computational biology, chemistry, systems biology, engineering, and clinical sciences is expected to generate more efficient discovery platforms capable of addressing complex global health challenges [116].

Artificial intelligence will likely become a central component of future pharmaceutical research. More sophisticated machine learning algorithms capable of integrating chemical structures, genomic information, clinical data, imaging datasets, and electronic health records will improve prediction of drug efficacy, toxicity, and therapeutic response [117]. Explainable artificial intelligence will further enhance confidence in computational predictions by providing biologically interpretable decision-making processes.

Digital biotechnology is expected to transform laboratory practice through automation, robotics, cloud computing, and digital twins. Automated laboratories capable of continuously learning from experimental outcomes will accelerate optimization of biosynthetic pathways and improve reproducibility across research institutions [118]. Integration of robotics with artificial intelligence will facilitate autonomous experimentation, allowing thousands of experimental conditions to be evaluated simultaneously.

Synthetic biology is also expected to undergo substantial expansion. Advances in DNA synthesis, modular pathway engineering, programmable genetic circuits, and artificial chromosomes will enable increasingly sophisticated redesign of microbial and plant metabolic networks [119]. Such technologies may permit biosynthesis of entirely new classes of therapeutic molecules that do not naturally occur in biological systems.

The continued refinement of CRISPR technologies will improve genome editing precision while reducing off-target effects. Emerging genome editing systems, including base editing and prime editing, provide greater flexibility for precise genetic modification without introducing double-stranded DNA breaks [120]. These technologies are expected to accelerate engineering of microbial cell factories, medicinal plants, and industrial production strains.

Single-cell omics represents another promising frontier. Conventional omics studies generally analyse populations of cells, thereby masking biological heterogeneity. Single-cell genomics, transcriptomics, proteomics, and metabolomics will provide unprecedented insight into cellular specialization and regulation of secondary metabolite biosynthesis [121]. Such knowledge will facilitate more precise engineering of biosynthetic pathways.

Natural products derived from extreme environments are expected to become increasingly important. Deep-sea ecosystems, deserts, polar regions, volcanic environments, and highly saline habitats harbour unique microorganisms that have evolved distinctive metabolic capabilities [122]. Exploration of these environments through metagenomics and advanced cultivation technologies may reveal entirely new classes of bioactive compounds.

Sustainability will remain a defining principle of future biotechnology. Green chemistry, renewable feedstocks, waste valorization, carbon-neutral bioprocessing, and circular bioeconomy strategies will increasingly guide industrial development [123]. Precision fermentation and engineered microbial systems are expected to replace

environmentally unsustainable extraction of scarce natural resources.

International collaboration will also become increasingly important. Modern drug discovery requires expertise spanning chemistry, biology, medicine, engineering, computer science, data analytics, pharmacology, toxicology, and regulatory science. Collaborative research networks will facilitate sharing of expertise, biological resources, computational infrastructure, and financial investment while accelerating translation of scientific discoveries into healthcare innovations [124].Ultimately, biotechnology is expected to fundamentally reshape the future of natural product research by enabling faster discovery, more sustainable production, improved therapeutic efficacy, and broader industrial application. Continued innovation, responsible governance, and interdisciplinary collaboration will determine the extent to which these technologies contribute to addressing emerging global health challenges.

8. Conclusion

Natural products remain one of the most valuable sources of structurally diverse bioactive molecules for pharmaceutical development and industrial biotechnology. Despite decades of scientific investigation, only a small fraction of Earth's biological diversity has been explored, indicating that enormous opportunities remain for the discovery of novel therapeutic agents.

The integration of genomics, genome mining, transcriptomics, proteomics, metabolomics, synthetic biology, metabolic engineering, CRISPR genome editing, artificial intelligence, and systems biology has fundamentally transformed natural product research. These complementary technologies have improved the efficiency of compound discovery, reduced rediscovery of known metabolites, enhanced production through engineered biological systems, and expanded opportunities for industrial commercialization.

Industrial biotechnology has similarly benefited from these technological advances, enabling sustainable production of pharmaceuticals, nutraceuticals, agricultural products, cosmetic ingredients, industrial enzymes, and environmentally friendly bioproducts. Biological manufacturing processes increasingly support global efforts toward sustainable development by reducing dependence on non-renewable resources and minimizing environmental impacts. Nevertheless, significant challenges remain. Analytical complexity, limited metabolite availability, cultivation difficulties, metabolic bottlenecks, regulatory requirements, data integration, biodiversity conservation, and commercialization barriers continue to influence the pace of innovation. Addressing these challenges will require continued investment in research infrastructure, computational technologies, international collaboration, and interdisciplinary education.

Looking ahead, the convergence of biotechnology with artificial intelligence, automation, precision genome editing, and multi-omics integration is expected to redefine natural product-based drug discovery. These innovations will accelerate identification of novel therapeutic molecules while supporting environmentally sustainable industrial production. As scientific understanding continues to expand, biotechnology will remain central to unlocking the immense pharmaceutical and industrial potential of nature's chemical diversity, thereby contributing significantly to global health, economic development, and environmental sustainability.

References

1. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200-216.
2. Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. Nat Chem. 2021;13(3):205-212.

3. Newman DJ, Cragg GM. Natural products as sources of new drugs over nearly four decades. J Nat Prod. 2020;83(3):770-803.
4. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2022;69:102175.
5. Rodrigues T, et al. Harnessing natural products for next-generation therapeutics. Nat Rev Chem. 2022;6(4):275-294.
6. Zhang MM, Wang Y, Ang EL, Zhao H. Engineering microbial hosts for natural product biosynthesis. Biotechnol Adv. 2022;59:107963.
7. Isah T. Stress and defense responses in medicinal plants affecting secondary metabolite production. Plant Cell Rep. 2021;40(6):1009-1026.
8. Navarro-Muñoz JC, Selem-Mojica N, Mullowney MW, et al. A computational framework for exploring biosynthetic diversity. Nat Chem Biol. 2020;16(1):60-68.
9. Kell DB, Oliver SG. Multi-omics approaches in biotechnology and systems biology. Nat Rev Mol Cell Biol. 2021;22(7):483-495.
10. Wolfender JL, Litaudon M, Touboul D, Queiroz EF. Innovative metabolomics approaches for natural product discovery. Nat Prod Rep. 2021;38(4):636-654.
11. Keasling JD. Synthetic biology and the future of natural product biosynthesis. ACS Synth Biol. 2022;11(2):507-520.
12. Zhao EM, Lalwani MA, Chen JM, et al. CRISPR technologies for metabolic engineering and natural product biosynthesis. Biotechnol Adv. 2023;65:108137.
13. Stokes JM, Yang K, Swanson K, et al. Artificial intelligence in antimicrobial and natural product discovery. Cell. 2023;186(2):239-257.
14. Nielsen J, Keasling JD. Engineering cellular metabolism for industrial biotechnology. Cell. 2022;185(15):2745-2756.
15. Misra BB, Langefeld C, Olivier M, Cox LA. Integrated multi-omics approaches in biotechnology. Brief Bioinform. 2022;23(1):bbab509.
16. Liu Y, Stewart CN Jr. Biotechnology regulations and commercialization of genetically engineered products. Trends Biotechnol. 2024;42(2):168-181.
17. Chandra S, Lata H, Varma A. Future perspectives of biotechnology-driven natural product research. Biotechnol Adv. 2025;74:108420.
18. Shen B. A new golden age of natural products drug discovery. Cell. 2021;184(18):4615-4617.
19. Salehi B, Sharifi-Rad J, Sestito S, et al. Resveratrol and other phytochemicals in modern drug discovery. Biotechnol Adv. 2021;49:107760.
20. Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR. Marine natural products. Nat Prod Rep. 2024;41(1):35-148.
21. Bérdy J. Thoughts and facts about antibiotics: where we are now and where we are heading. J Antibiot. 2022;75(8):421-435.
22. Albarano L, Esposito R, Ruocco N, Costantini M. Genome mining in microorganisms for novel natural products. Mar Drugs. 2020;18(4):199.
23. Durazzo A, Lucarini M, Souto EB, et al. Polyphenols: from pharmacology to drug discovery. Molecules. 2021;26(5):1377.
24. Jiménez C. Marine natural products in drug discovery: recent advances and future prospects. Mar Drugs. 2023;21(2):116.
25. Chen SL, Yu H, Luo HM, Wu Q, Li CF, Steinmetz A. Conservation and sustainable utilization of medicinal plant resources. Plant Divers. 2021;43(5):373-382.
26. Miethke M, Pieroni M, Weber T, et al. Towards the sustainable discovery of new antibiotics. Nat Rev Chem. 2021;5(10):726-749.
27. Ortiz A, Sansinenea E. Industrial applications of microbial natural products. World J Microbiol Biotechnol. 2022;38:158.
28. Clevenger KD, Bok JW, Ye R, et al. Integrating omics technologies for natural product discovery. Nat Rev Microbiol. 2023;21(6):371-388.

29. Witting M, Aksenov AA, Luzzatto-Knaan T, et al. Multi-omics approaches accelerate natural product discovery. Trends Biotechnol. 2023;41(10):1320-1335.
30. Zhang W, Zeng Y, Jiao M, et al. Integration of high-throughput omics technologies in medicinal plant research: the new era of natural drug discovery. Front Plant Sci. 2023;14:1073848.
31. Albarano L, Esposito R, Ruocco N, Costantini M. Genome mining for bioactive natural products from microorganisms. Mar Drugs. 2020;18(4):199.
32. Metcalf WW, van der Donk WA. Biosynthetic gene clusters and comparative genomics in natural product discovery. Nat Prod Rep. 2021;38(11):2085-2104.
33. Zhang W, Zeng Y, Jiao M, et al. Chromosome-scale genomics of medicinal plants for natural product biosynthesis. Front Plant Sci. 2023;14:1073848.
34. Clevenger KD, Bok JW, Ye R, et al. Genome mining strategies for modern natural product discovery. Nat Rev Microbiol. 2023;21(6):371-388.
35. Terlouw BR, van Santen JA, et al. MIBiG 3.0: community annotation of experimentally validated biosynthetic gene clusters. Nucleic Acids Res. 2023;51:D603-D610.
36. Gaudêncio SP, Bayram E, Bilela LL, et al. Advanced methods for natural products discovery. Nat Prod Rep. 2023;40:1967-2018.
37. The Deep Mining Era: Genomic, Metabolomic, and Integrative Approaches to Microbial Natural Products from 2018 to 2024. Microorganisms. 2025.
38. Zhang W, Zeng Y, Jiao M, et al. Transcriptomics in medicinal plant natural product research. Front Plant Sci. 2023;14:1073848.
39. Zhang W, Zeng Y, Jiao M, et al. RNA sequencing applications in medicinal plants. Front Plant Sci. 2023;14:1073848.
40. Zhang W, Zeng Y, Jiao M, et al. Multi-omics-guided elucidation of biosynthetic pathways in medicinal plants. Front Plant Sci. 2023;14:1073848.
41. Metabolomics and Genomics in Natural Products Research: Complementary Tools for Targeting New Chemical Entities. ACS Chem Biol. 2021.
42. Zhang W, Zeng Y, Jiao M, et al. Proteomics in medicinal plant biotechnology. Front Plant Sci. 2023;14:1073848.
43. Choi YH, Jang YP, Frédérich M. Applications of metabolomics to the discovery of biomolecules from natural products. Front Mol Biosci. 2023;10:1190730.
44. Metabolomics and Genomics in Natural Products Research. ACS Chem Biol. 2021.
45. Zhang W, Zeng Y, Jiao M, et al. Integrated proteomics for natural product biosynthesis. Front Plant Sci. 2023;14:1073848.
46. Wolfender JL, Litaudon M, Touboul D, Queiroz EF. Innovative metabolomics approaches for natural product discovery. Nat Prod Rep. 2021;38:636-654.
47. Choi YH, Jang YP, Frédérich M. Editorial: Applications of metabolomics to the discovery of biomolecules from natural products. Front Mol Biosci. 2023;10:1190730.
48. Lee SY, Kim HU. Systems metabolic engineering for industrial biotechnology. Trends Biotechnol. 2022.
49. Gaudêncio SP, Bayram E, Bilela LL, et al. Advanced methods for natural products discovery. Nat Prod Rep. 2023;40:1967-2018.
50. Mullowney MW, Duncan KR, Elsayed SS, et al. Artificial intelligence for natural product drug discovery. Nat Rev Drug Discov. 2023;22:895-916.
51. Ke J, Wang B, Zhang H, et al. Synthetic biology of natural products engineering: recent advances across the discover-design-build-test-learn cycle. ACS Synth Biol. 2024.
52. Hug JJ, Krug D, Müller R. Bacteria as genetically programmable producers of bioactive natural products. Nat Rev Chem. 2020;4:172-193.

53. Voigt CA. Synthetic biology 2020-2030: six commercially available products that are changing our world. Nat Commun. 2020;11:6379.
54. Naseri G, Koffas MAG. Application of combinatorial optimization strategies in synthetic biology. Nat Commun. 2020;11:2446.
55. Nielsen J. Synthetic biology for engineering natural product biosynthesis. Curr Opin Biotechnol. 2021.
56. Silver PA, Way JC. Engineering biological systems through synthetic biology. Cell. 2021.
57. Keasling JD. Engineering microbial metabolism for production of natural products. Cell. 2022.
58. Lee SY, Kim HU. Systems metabolic engineering for industrial biotechnology. Trends Biotechnol. 2022.
59. Stephanopoulos G. Metabolic engineering: principles and applications in biotechnology. Metab Eng. 2021.
60. Nielsen J, Keasling JD. Engineering cellular metabolism for industrial biotechnology. Cell. 2022;185:2745-2756.
61. Zhang Y, Wang G, Li S. Advances in microbial metabolic engineering for natural product biosynthesis. Biotechnol Adv. 2022.
62. Liu R, Zhang C. Dynamic pathway regulation in metabolic engineering. Curr Opin Biotechnol. 2023.
63. Kim S, Lee JW. Systems metabolic engineering integrating multi-omics technologies. Biotechnol J. 2023.
64. Ajikumar PK, Tyo K, Stephanopoulos G. Industrial applications of engineered microbial cell factories. Biotechnol Adv. 2022.
65. Lee JW, Na D, Park JM, Lee J, Choi S, Lee SY. Systems biotechnology for sustainable biomanufacturing. Trends Biotechnol. 2021.
66. Chae TU, Choi SY, Kim JW, Ko YS, Lee SY. Recent advances in systems metabolic engineering. Curr Opin Biotechnol. 2023.
67. Pickar-Oliver A, Gersbach CA. The next generation of CRISPR technologies. Nat Rev Mol Cell Biol. 2020.
68. Adli M. The CRISPR toolbox for genome engineering. Nat Commun. 2021.
69. Wang H, Russa ML, Qi LS. CRISPR technologies for biological discovery and biotechnology. Nat Rev Mol Cell Biol. 2021.
70. Jinek M, Doudna JA. CRISPR genome editing for biotechnology applications. Science. 2021.
71. Zhao EM, Lalwani MA, Chen JM, et al. CRISPR technologies for metabolic engineering and natural product biosynthesis. Biotechnol Adv. 2023.
72. Liu D, Huang L. CRISPR-based engineering of microbial cell factories. Curr Opin Biotechnol. 2024.
73. Gao C. Genome editing technologies in plants and microorganisms. Annu Rev Plant Biol. 2021.
74. Chen X, Li Y. Genome editing strategies for industrial biotechnology. Biotechnol Adv. 2025.
75. Muthuraj R, Chandrasekaran J. Nature meets machine: the AI renaissance in natural product drug discovery. Nat Prod Bioprospect. 2026.
1. Springer Link
76. Mullowney MW, Duncan KR, Elsayed SS, et al. Artificial intelligence for natural product drug discovery. Nat Rev Drug Discov. 2023.
77. Stokes JM, Yang K, Swanson K, et al. Artificial intelligence approaches for antimicrobial discovery. Cell. 2023.
78. Wolfender JL, Queiroz EF, et al. Computational metabolomics in natural product research. Nat Prod Rep. 2021.
79. Choi YH, Jang YP, Frédérich M. Applications of metabolomics to the discovery of biomolecules from natural products. Front Mol Biosci. 2023.
80. Gao W, Coley CW. Artificial intelligence for molecular design and drug discovery. Nat Mach Intell. 2021.
81. Wang Z, Zhao Y, Wang B. Artificial intelligence for natural product drug discovery and development: current landscape, applications, and future directions. Drug Discov Today. 2025.

82. Liao L, Xie M, Zheng X, Zhou Z, Deng Z, Gao J. Molecular insights fast-tracked: AI in biosynthetic pathway research. Nat Prod Rep. 2025;42:911-936.
83. Mullowney MW, Duncan KR, Elsayed SS, et al. Artificial intelligence for natural product drug discovery. Nat Rev Drug Discov. 2023;22:895-916.
84. Choi YH, Jang YP, Frédérich M. Molecules to medicine: advances in metabolomics for natural product drug discovery. Curr Opin Biotechnol. 2025;96:103373.
85. Nielsen J, Keasling JD. Engineering cellular metabolism for industrial biotechnology. Cell. 2022;185(15):2745-2756.
86. Lee SY, Kim HU. Systems metabolic engineering for industrial biotechnology. Trends Biotechnol. 2022;40:106-121.
87. Keasling JD. Synthetic biology and the development of microbial cell factories. ACS Synth Biol. 2022;11:507-520.
88. Zhang MM, Wang Y, Ang EL, Zhao H. Engineering microbial hosts for natural product biosynthesis. Biotechnol Adv. 2022;59:107963.
89. Durazzo A, Lucarini M, Souto EB, et al. Polyphenols: from pharmacology to nutraceutical development. Molecules. 2021;26:1377.
90. Isah T. Stress responses and secondary metabolite production in medicinal plants. Plant Cell Rep. 2021;40:1009-1026.
91. Ortiz A, Sansinenea E. Industrial applications of microbial natural products. World J Microbiol Biotechnol. 2022;38:158.
92. Chen SL, Yu H, Luo HM, Wu Q, Li CF, Steinmetz A. Conservation and sustainable utilization of medicinal plant resources. Plant Divers. 2021;43:373-382.
93. Gaudêncio SP, Bayram E, Bilela LL, et al. Advanced methods for natural products discovery. Nat Prod Rep. 2023;40:1967-2018.
94. Clevenger KD, Bok JW, Ye R, et al. Integrating omics technologies for natural product discovery. Nat Rev Microbiol. 2023;21:371-388.
95. Witting M, Aksenov AA, Luzzatto-Knaan T, et al. Multi-omics approaches accelerate natural product discovery. Trends Biotechnol. 2023;41:1320-1335.
96. Zhang W, Zeng Y, Jiao M, et al. Integration of omics technologies in medicinal plant research. Front Plant Sci. 2023;14:1073848.
97. Barber HM, Pater A, Gagnon KT, et al. Chemical engineering of CRISPR-Cas systems for therapeutic application. Nat Rev Drug Discov. 2025;24:209-230.
98. Liu Y, Stewart CN Jr. Biotechnology regulations and commercialization of genetically engineered products. Trends Biotechnol. 2024;42:168-181.
99. Muthuraj R, Chandrasekaran J. Nature meets machine: the AI renaissance in natural product drug discovery. Nat Prod Bioprospect. 2026.
100. Gao W, Coley CW. Artificial intelligence and molecular design for next-generation drug discovery. Nat Mach Intell. 2021.
101. Tong Y, Weber T. Revolutionizing biotechnology advances natural products discovery and industrial processing. Synth Syst Biotechnol. 2024;10(1):156-157.
102. Meijer D, Beniddir MA, Coley CW, van der Hooft JJJ, Medema MH, Skiredj A. Empowering natural product science with AI: leveraging multimodal data and knowledge graphs. Nat Prod Rep. 2025;42:654-662.
103. Liao L, Xie M, Zheng X, Zhou Z, Deng Z, Gao J. Molecular insights fast-tracked: AI in biosynthetic pathway research. Nat Prod Rep. 2025;42:911-936.
104. Isoko K, Cordiner JL, Kis Z, Moghadam PZ. Bioprocessing 4.0: a pragmatic review and future perspectives. Digit Discov. 2024;3:1662-1681.
105. Tong Y, Weber T. Advances in genome editing tools and applications for natural products and industrial biotechnology. Synth Syst Biotechnol. 2024;10(1):156-157.
106. Meijer D, van der Hooft JJJ, Medema MH, Skiredj A. Artificial intelligence and multimodal data integration in natural product research. Nat Prod Rep. 2025;42:654-662.

107. Liao L, Xie M, Zheng X, Deng Z, Gao J. Artificial intelligence for pathway discovery, design and optimization of natural product biosynthesis. Nat Prod Rep. 2025;42:911-936.
108. Tong Y, Weber T. Genome editing technologies for microbial natural product biosynthesis. Synth Syst Biotechnol. 2024;10(1):156-157.
109. Isoko K, Cordiner JL, Kis Z, Moghadam PZ. Digital transformation and Industry 4.0 in bioprocess engineering. Digit Discov. 2024;3:1662-1681.
110. Meijer D, Beniddir MA, Coley CW, et al. Knowledge graph technologies for accelerating natural product discovery. Nat Prod Rep. 2025;42:654-662.
111. Liao L, Xie M, Zheng X, et al. Machine learning strategies for biosynthetic pathway engineering. Nat Prod Rep. 2025;42:911-936.
112. Tong Y, Weber T. Future directions in genome editing for industrial biotechnology. Synth Syst Biotechnol. 2024;10(1):156-157.
113. Isoko K, Cordiner JL, Kis Z, Moghadam PZ. Artificial intelligence and digital twins in industrial bioprocessing. Digit Discov. 2024;3:1662-1681.
114. Meijer D, van der Hooft JJJ, Medema MH, et al. Future perspectives of AI-assisted natural product science. Nat Prod Rep. 2025;42:654-662.
115. Liao L, Xie M, Zheng X, et al. Artificial intelligence for metabolic pathway optimization. Nat Prod Rep. 2025;42:911-936.
116. Tong Y, Weber T. Emerging genome editing technologies in industrial biotechnology. Synth Syst Biotechnol. 2024;10(1):156-157.
117. Meijer D, Beniddir MA, Coley CW, et al. AI-enabled integration of omics data in natural product discovery. Nat Prod Rep. 2025;42:654-662.
118. Isoko K, Cordiner JL, Kis Z, Moghadam PZ. Digital biomanufacturing and future industrial biotechnology. Digit Discov. 2024;3:1662-1681.
119. Liao L, Xie M, Zheng X, et al. Integrating artificial intelligence with synthetic biology for natural product biosynthesis. Nat Prod Rep. 2025;42:911-936.
120. Tong Y, Weber T. CRISPR technologies and industrial biotechnology: future opportunities. Synth Syst Biotechnol. 2024;10(1):156-157.
121. Meijer D, Beniddir MA, Coley CW, et al. Multimodal artificial intelligence in natural product science. Nat Prod Rep. 2025;42:654-662.
122. Isoko K, Cordiner JL, Kis Z, Moghadam PZ. Smart biomanufacturing and the future of industrial biotechnology. Digit Discov. 2024;3:1662-1681.
123. Liao L, Xie M, Zheng X, et al. AI-driven biosynthetic pathway optimization for sustainable biotechnology. Nat Prod Rep. 2025;42:911-936.
124. Tong Y, Weber T. Outlook for biotechnology, genome editing and natural product biosynthesis. Synth Syst Biotechnol. 2024;10(1):156-157.

Access this Article in Online	
Quick Response Code	Website: www.ijcrcps.com
	Subject: Biotechnology
DOI: 10.22192/ijcrcps.2026.13.08.001	

How to cite this article:
Hussein Muhammed, Yunusa Lawal, Ibrahim Usman. (2026). Biotechnological Approaches in Natural Product-Based Drug Discovery and Industrial Biotechnology: Current Advances and Future Perspectives. Int. J. Curr. Res. Chem. Pharm. Sci. 13(8): 1-24.
DOI: http://dx.doi.org/10.22192/ijcrcps.2026.13.08.001